Placebo to Ezetimibe
Sponsors
Organon and Co, Amgen
Conditions
HypercholesterolemiaHyperlipidemia
Phase 3
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)
CompletedNCT01370590
Start: 2011-09-30End: 2012-04-30Updated: 2022-02-09
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)
CompletedNCT01370603
Start: 2011-09-30End: 2012-05-31Updated: 2022-02-09
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2
CompletedNCT01763905
Start: 2013-01-24End: 2013-11-19Updated: 2020-07-20
LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2
CompletedNCT01763866
Start: 2013-01-15End: 2013-12-04Updated: 2022-11-08
Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2
CompletedNCT01763827
Start: 2013-01-21End: 2013-10-29Updated: 2022-11-08
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3
CompletedNCT01984424
Start: 2013-12-10End: 2017-11-21Updated: 2018-11-29